Fennec Pharmaceuticals Inc FENC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FENC is a good fit for your portfolio.
News
-
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
-
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
-
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
-
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
Trading Information
- Previous Close Price
- $9.16
- Day Range
- $9.04–9.30
- 52-Week Range
- $6.30–11.92
- Bid/Ask
- $8.37 / $9.87
- Market Cap
- $249.59 Mil
- Volume/Avg
- 154,291 / 137,175
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.fennecpharma.com
Comparables
Valuation
|
Metric
|
FENC
|
NYKD
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.43 | 0.97 |
Price/Sales | 11.52 | 28.54 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
FENC
NYKD
EQRX
Financial Strength
|
Metric
|
FENC
|
NYKD
|
EQRX
|
|---|---|---|---|
Quick Ratio | 2.92 | 7.91 | 18.43 |
Current Ratio | 3.56 | 8.04 | 18.78 |
Interest Coverage | −3.86 | −235.75 | — |
Quick Ratio
FENC
NYKD
EQRX
Profitability
|
Metric
|
FENC
|
NYKD
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −46.70% | −19.18% | −15.72% |
Return on Equity (Normalized) | — | −26.31% | −16.71% |
Return on Invested Capital (Normalized) | −42.68% | −30.96% | −21.31% |
Return on Assets
FENC
NYKD
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tgjhmscmg | Gqd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nkhkwcs | Zxfdqk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Thfrhdwd | Pvrwhhy | $97.8 Bil | |
MRNA
| Moderna Inc | Kgvzjjy | Bcqd | $41.3 Bil | |
ARGX
| argenx SE ADR | Crhcgrqj | Hpps | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ftwhzpmky | Szfy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hvhgpbxrp | Tlmnnll | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gfqxxsxzp | Sjlcrj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vqmdswzrn | Mylwv | $12.5 Bil | |
INCY
| Incyte Corp | Xpttrbzc | Jmvlbcx | $11.6 Bil |